- Fee assured
- Verified this account
Dr Parker is a Consultant Rheumatologist and Honorary Senior Lecturer at University of Manchester. He offers a private rheumatology service at Spire Manchester for both general and specialist conditions. He specialises in the management of complex connective tissue diseases, specifically systemic lupus erythematosus (SLE) and vasculitis. He also offers a general rheumatology service, young adult transition clinics, and runs the rheumatology biologics service at Manchester Royal Infirmary. Dr Parker acts as Principal Investigator on several early phase clinical trials in SLE, is an active researcher in the Manchester Biomedical Research Centre, and is Medical Director of the (Adult) Manchester Clinical Research Facility at Central Manchester University Hospitals.
Areas of interest
General rheumatology; Systemic lupus erythematous; vasculitis; Connective tissue diseases; Musculoskeletal pain; Regional and Widespread Pain syndromes; Fibromyalgia; Osteoarthritis; Rheumatoid arthritis; Psoriatic and other inflammatory arthritis; Soft tissue rheumatism; Osteoporosis.
Systemic lupus erythematosus; Connective tissue diseases;
joint injections; soft tissue injections
Current NHS consultant posts held
Kellgren Centre for Rheumatology, Manchester Royal Infirmary
Dr Parker is actively involved in research into outcomes and treatment of systemic lupus erythematosus and related connective tissue diseases. He has authored many research articles and presented his research at national and international conferences.
British Society of Rheumatology Outstanding Best Practice Award 2016
NICE Shared LearningAward 2017
Parker B, Bruce IN. Landmark Papers in Lupus p121-153. Landmark Papers in Rheumatology. Oxford University Press; 1st Ed. Ed Watts and Scott. 2015.
Recent Research Articles
McCarthy EM, Sutton E; Nesbit S; Parker B; Jayne D; Griffiths B; Isenberg D; Rahman A; Gordon C; D'Cruz D; Rhodes B; Lanyon P; Vital E; Yee CS; Edwards Cr; The LS; Zoma A; Akil M; McHugh N; Bruce IN. Short-term efficacy and safety of Rituximab therapy in refractory SLE: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology (Oxford). 2017 Jun 1;56(6):1049. doi: 10.1093
Little J, Parker B, et al. An exploration of factors associated with the use of glucocorticoids in the Systemic Lupus International Collaborating Clinics Inception Cohort. Accepted Rheumatology 2017.
Mendoza-Pinto C, Pirone C, van der Windt D, Parker B, Bruce IN. Can We Identify Who Gets Benefit or Harm from rituximab in Systemic Lupus Erythematosus? A Systematic Review. Semin Arthritis Rheum. 2017 May 5. pii: S0049-0172(17)30099-9..
Mendoza-Pinto C, Pirone C, van der Windt D, Parker B, Bruce IN. Can We Identify Who Gets Benefit or Harm from Mycophenolate Mofetil in Systemic Lupus Erythematosus? A Systematic Review. Semin Arthritis Rheum. 2017 Aug;47(1):65-78. doi: 10.1016
Green D, Skeoch S, Alexander MY, Kalra PA, Parker B. Longitudinal change in endothelial microparticle count is associated with mortality in chronic kidney disease. Nephron. 2017 Jan 25. doi: 10.1159/000452344
McCarthy EM, Moreno D, Wilkinson F, McHugh N, Bruce IN, Alexander MY, Parker B. Microparticle Subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of Connective Tissue Disease. BBA Clin. 2016 Nov 10;7:16-22. doi: 10.1016
- MBChB (with Honours) University of Liverpool 2000
- MRCP Royal College of Physicians (Ed) 2005
- PhD University of Manchester 2012
- FRCP Royal College of Physicians 2017
Details of entry to specialist register
- General Medical Council CCT in Rheumatology, 2013
Affiliations / memberships
General Medical Council
Royal College of Physicians (Edinburgh)
Medical Defence Union
British Society for Rheumatology
- Spire Manchester
- 16:30 - 20:30
- 0161 885 530
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
myself via my PA or hospital switchboard